A detailed history of Geode Capital Management, LLC transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 460,140 shares of CRVS stock, worth $3.96 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
460,140
Previous 371,763 23.77%
Holding current value
$3.96 Million
Previous $661,000 26.63%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$1.36 - $2.29 $120,192 - $202,383
88,377 Added 23.77%
460,140 $837,000
Q1 2024

May 13, 2024

BUY
$1.76 - $2.41 $20,034 - $27,433
11,383 Added 3.16%
371,763 $661,000
Q3 2023

Nov 13, 2023

BUY
$1.41 - $2.97 $25,804 - $54,353
18,301 Added 5.35%
360,380 $526,000
Q2 2023

Aug 11, 2023

BUY
$1.0 - $3.86 $44,279 - $170,916
44,279 Added 14.87%
342,079 $783,000
Q4 2022

Feb 13, 2023

SELL
$0.74 - $1.04 $488 - $686
-660 Reduced 0.22%
297,800 $253,000
Q1 2022

May 13, 2022

BUY
$1.46 - $2.48 $19,835 - $33,693
13,586 Added 4.77%
298,460 $489,000
Q4 2021

Feb 11, 2022

BUY
$2.34 - $5.31 $174,636 - $396,290
74,631 Added 35.5%
284,874 $686,000
Q3 2021

Nov 12, 2021

BUY
$1.89 - $8.53 $39,126 - $176,588
20,702 Added 10.92%
210,243 $1.02 Million
Q2 2021

Aug 13, 2021

BUY
$2.46 - $3.14 $100,139 - $127,819
40,707 Added 27.35%
189,541 $506,000
Q1 2021

May 12, 2021

BUY
$2.86 - $4.77 $109,177 - $182,089
38,174 Added 34.5%
148,834 $458,000
Q4 2020

Feb 12, 2021

SELL
$3.56 - $4.86 $3,161 - $4,315
-888 Reduced 0.8%
110,660 $393,000
Q3 2020

Nov 13, 2020

SELL
$2.6 - $5.37 $85,316 - $176,211
-32,814 Reduced 22.73%
111,548 $447,000
Q2 2020

Aug 13, 2020

BUY
$2.01 - $4.05 $10,946 - $22,056
5,446 Added 3.92%
144,362 $392,000
Q1 2020

May 14, 2020

BUY
$1.74 - $5.98 $2,368 - $8,138
1,361 Added 0.99%
138,916 $293,000
Q4 2019

Feb 13, 2020

BUY
$2.56 - $5.44 $20,986 - $44,597
8,198 Added 6.34%
137,555 $748,000
Q3 2019

Nov 12, 2019

BUY
$3.01 - $6.5 $43,834 - $94,659
14,563 Added 12.69%
129,357 $389,000
Q2 2019

Aug 14, 2019

SELL
$3.3 - $4.58 $158,720 - $220,284
-48,097 Reduced 29.53%
114,794 $429,000
Q1 2019

May 14, 2019

BUY
$3.75 - $4.97 $39,487 - $52,334
10,530 Added 6.91%
162,891 $654,000
Q4 2018

Feb 13, 2019

BUY
$3.29 - $8.94 $80,019 - $217,438
24,322 Added 19.0%
152,361 $559,000
Q3 2018

Nov 13, 2018

BUY
$8.58 - $11.4 $40,205 - $53,420
4,686 Added 3.8%
128,039 $1.1 Million
Q2 2018

Aug 14, 2018

BUY
$9.42 - $13.73 $446,423 - $650,678
47,391 Added 62.39%
123,353 $1.35 Million
Q1 2018

May 15, 2018

BUY
$7.48 - $11.53 $14,683 - $22,633
1,963 Added 2.65%
75,962 $875,000
Q4 2017

Feb 13, 2018

BUY
$9.3 - $16.93 $5,821 - $10,598
626 Added 0.85%
73,999 $766,000
Q3 2017

Nov 14, 2017

BUY
$11.3 - $17.23 $51,968 - $79,240
4,599 Added 6.69%
73,373 $1.17 Million
Q2 2017

Aug 14, 2017

BUY
N/A
68,774
68,774 $832,000

Others Institutions Holding CRVS

About Corvus Pharmaceuticals, Inc.


  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $401M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.